[The effect of entecavir treatment on HBV-specific immunity in patient with chronic hepatitis B and its relationship to HBeAg sero-conversion].
OBJECTIVE
To investigate the effect of Entecavir treatment on HBV-specific immunity in patient with chronic hepatitis B and its relationship to HBeAg sero-conversion.


METHODS
Serum aminotransferase (ALT), HBV DNA and HBeAg were monitored before the after entecavir treatment. At the same time point, HBV-specific T cell proliferation was determined by [3H] T-dR incorporation assay, while HBV-specific IFN-alpha secretion was measured by ELISA.


RESULTS
The level of HBV DNA and ALT was significantly decreased after entecavir treatment. Same is the titer of HBeAg. In addition, HBeAg sero-conversion was observed in some of them, in whom the HBV-specific T cell proliferation and IFN-alpha production were significantly increased.


CONCLUSIONS
Entecavir treatment resulted in increased HBV-specific immunity along with the inhibition of HBV replication.
Li
Jian-xiang
JX
Shenzhen Luohu Hospital, Shenzhen, China.
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D049109:Cell Proliferation / Q000187:drug effects; D004279:DNA, Viral / Q000097:blood / Q000235:genetics; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006513:Hepatitis B e Antigens / Q000097:blood*; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000097:blood; D008297:Male; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects; D013997:Time Factors; D000637:Transaminases / Q000097:blood; D016896:Treatment Outcome
D000998:Antiviral Agents; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D016898:Interferon-alpha; C413685:entecavir; D006147:Guanine; D000637:Transaminases